Comparison between leflunomide and sulfasalazine based triple therapy in methotrexate refractory rheumatoid arthritis: an open-label, non-inferiority randomized controlled trial

To compare efficacy and safety of two different combination csDMARD therapy in Methotrexate-failed Rheumatoid arthritis patients. In this 24-week open-label, parallel-group non-inferiority, single-center clinical trial, Methotrexate-failed Rheumatoid arthritis patients with disease duration 

Saved in:
Bibliographic Details
Published in:Rheumatology international 2022-05, Vol.42 (5), p.771-782
Main Authors: Belani, Pooja J., Kavadichanda, Chengappa G., Negi, Vir Singh
Format: Article
Language:English
Subjects:
Antibiotics
Antirheumatic Agents - adverse effects
Arthritis, Rheumatoid - chemically induced
Arthritis, Rheumatoid - diagnosis
Arthritis, Rheumatoid - drug therapy
Clinical Trials
Confidence intervals
Drug Therapy, Combination
Humans
Hydroxychloroquine - adverse effects
Leflunomide - adverse effects
Medicine
Medicine & Public Health
Methotrexate - adverse effects
Rheumatoid arthritis
Rheumatology
Sulfasalazine - adverse effects
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To compare efficacy and safety of two different combination csDMARD therapy in Methotrexate-failed Rheumatoid arthritis patients. In this 24-week open-label, parallel-group non-inferiority, single-center clinical trial, Methotrexate-failed Rheumatoid arthritis patients with disease duration 
ISSN:1437-160X
0172-8172
1437-160X
DOI:10.1007/s00296-021-04994-1